Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15881127 | 0.72 | CACNA1F (0.37) | POLBCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL29287288 | 0.69 | POLB (0.35) | POLBEDNRA | |
| SCHEMBL1667303 | 0.68 | POLB (0.40) | POLBGAAEDNRA | |
| SCHEMBL13155158 | 0.64 | EPHX2 (0.49) | POLBEDNRA | |
| SCHEMBL8440538 | 0.64 | MEN1 (0.32) | — | |
| SCHEMBL9852781 | 0.64 | KMT2A (0.33) | GAA | |
| SCHEMBL15881089 | 0.63 | HCAR2 (0.46) | POLB | |
| SCHEMBL29287290 | 0.63 | CHRNA4 (0.33) | — | |
| SCHEMBL6632393 | 0.63 | TMPRSS15 (0.55) | POLBGAA | |
| SCHEMBL30455939 | 0.62 | CHRNA4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | POLB 4759/4885CACNA1F 1069/4885CACNA1D 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.